Benign Prostatic Hyperplasia Treatment Market by Type [Drug (Alpha Blockers(Tamsulosin, Doxazosin), 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride), Surgical Treatment (TURP, TUMT, TUNA], End User (Hospitals) - Global Industry Analysis, Share ,Growth ,Regional Outlook And Forecasts, 2021-2027

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Benign Prostatic Hyperplasia Treatment Market, By Type

7.1.  Benign Prostatic Hyperplasia Treatment Market, by Type, 2021-2027

7.1.1.     Drug Treatment

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Alpha Blockers

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     5-Aplha Reductase Inhibitors

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     ther Drug Classes

7.1.4.1.          Market Revenue and Forecast (2016-2027)

7.1.5.     Surgical Treatment

7.1.5.1.          Market Revenue and Forecast (2016-2027)

7.1.6.     Transurethral Resection of the Prostate (TURP)

7.1.6.1.          Market Revenue and Forecast (2016-2027)

7.1.7.     Transurethral Microwave Thermotherapy (TUMT)

7.1.7.1.          Market Revenue and Forecast (2016-2027)

7.1.8.     Transurethral Needle Ablation of the Prostate (TUNA)

7.1.8.1.          Market Revenue and Forecast (2016-2027)

7.1.9.     Laser Therapy

7.1.9.1.          Market Revenue and Forecast (2016-2027)

7.1.10.  Prostatic Stenting

7.1.10.1.       Market Revenue and Forecast (2016-2027)

7.1.11.  UroLift Therapy

7.1.11.1.       Market Revenue and Forecast (2016-2027)

7.1.12.  Rezûm Therapy

7.1.12.1.       Market Revenue and Forecast (2016-2027)

7.1.13.  Rezûm Therapy

7.1.13.1.       Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Benign Prostatic Hyperplasia Treatment Market, Regional Estimates and Trend Forecast

8.1.  North America

8.1.1.     Market Revenue and Forecast, by Type (2016-2027)

8.1.2.     U.S.

8.1.3.     Rest of North America

8.1.3.1.          Market Revenue and Forecast, by Type (2016-2027)

8.2.  Europe

8.2.1.     Market Revenue and Forecast, by Type (2016-2027)

8.2.2.     UK

8.2.2.1.          Market Revenue and Forecast, by Type (2016-2027)

8.2.3.     France

8.2.3.1.          Market Revenue and Forecast, by Type (2016-2027)

8.2.4.     Rest of Europe

8.2.4.1.          Market Revenue and Forecast, by Type (2016-2027)

8.3.  APAC

8.3.1.     Market Revenue and Forecast, by Type (2016-2027)

8.3.2.     India

8.3.2.1.          Market Revenue and Forecast, by Type (2016-2027)

8.3.3.     China

8.3.3.1.          Market Revenue and Forecast, by Type (2016-2027)

8.3.4.     Japan

8.3.4.1.          Market Revenue and Forecast, by Type (2016-2027)

8.3.5.     Rest of APAC

8.3.5.1.          Market Revenue and Forecast, by Type (2016-2027)

8.4.  MEA

8.4.1.     Market Revenue and Forecast, by Type (2016-2027)

8.4.2.     GCC

8.4.2.1.          Market Revenue and Forecast, by Type (2016-2027)

8.4.3.     North Africa

8.4.3.1.          Market Revenue and Forecast, by Type (2016-2027)

8.4.4.     South Africa

8.4.4.1.          Market Revenue and Forecast, by Type (2016-2027)

8.4.5.     Rest of MEA

8.4.5.1.          Market Revenue and Forecast, by Type (2016-2027)

8.5.  Latin America

8.5.1.     Market Revenue and Forecast, by Type (2016-2027)

8.5.2.     Brazil

8.5.2.1.          Market Revenue and Forecast, by Type (2016-2027)

8.5.3.     Rest of LATAM

8.5.3.1.          Market Revenue and Forecast, by Type (2016-2027)

Chapter 9.      Company Profiles

9.1.  Boston Scientific Corporation (US)

9.1.1.     Company Overview

9.1.2.     Product Offerings

9.1.3.     Financial Performance

9.1.4.     Recent Initiatives

9.2.  Coloplast Group (Denmark)

9.2.1.     Company Overview

9.2.2.     Product Offerings

9.2.3.     Financial Performance

9.2.4.     Recent Initiatives

9.3.  Teleflex Incorporated (US)

9.3.1.     Company Overview

9.3.2.     Product Offerings

9.3.3.     Financial Performance

9.3.4.     Recent Initiatives

9.4.  Olympus Corporation (Japan)

9.4.1.     Company Overview

9.4.2.     Product Offerings

9.4.3.     Financial Performance

9.4.4.     Recent Initiatives

9.5.  GlaxoSmithKline PLC (UK)

9.5.1.     Company Overview

9.5.2.     Product Offerings

9.5.3.     Financial Performance

9.5.4.     Recent Initiatives

9.6.  Eli Lilly (US)

9.6.1.     Company Overview

9.6.2.     Product Offerings

9.6.3.     Financial Performance

9.6.4.     Recent Initiatives

9.7.  Pfizer, Inc. (US)

9.7.1.     Company Overview

9.7.2.     Product Offerings

9.7.3.     Financial Performance

9.7.4.     Recent Initiatives

9.8.  Abbott (US)

9.8.1.     Company Overview

9.8.2.     Product Offerings

9.8.3.     Financial Performance

9.8.4.     Recent Initiatives

9.9.  Asahi Kasei Corporation (Japan)

9.9.1.     Company Overview

9.9.2.     Product Offerings

9.9.3.     Financial Performance

9.9.4.     Recent Initiatives

9.10.                 Merck & Co., Inc. (US)

9.10.1.  Company Overview

9.10.2.  Product Offerings

9.10.3.  Financial Performance

9.10.4.  Recent Initiatives

9.11.                 Astellas Pharma Inc. (Japan)

9.11.1.  Company Overview

9.11.2.  Product Offerings

9.11.3.  Financial Performance

9.11.4.  Recent Initiatives

9.12.                 Allergan plc (Ireland)

9.12.1.  Company Overview

9.12.2.  Product Offerings

9.12.3.  Financial Performance

9.12.4.  Recent Initiatives

9.13.                 Alembic (India)

9.13.1.  Company Overview

9.13.2.  Product Offerings

9.13.3.  Financial Performance

9.13.4.  Recent Initiatives

9.14.                 IPG Photonics Corporation (US)

9.14.1.  Company Overview

9.14.2.  Product Offerings

9.14.3.  Financial Performance

9.14.4.  Recent Initiatives

9.15.                 ichard Wolf GmbH (Germany)

9.15.1.  Company Overview

9.15.2.  Product Offerings

9.15.3.  Financial Performance

9.15.4.  Recent Initiatives

9.16.                 Unilab, Inc. (Philippines)

9.16.1.  Company Overview

9.16.2.  Product Offerings

9.16.3.  Financial Performance

9.16.4.  Recent Initiatives

9.17.                 Pharex Health Corporation (Philippines)

9.17.1.  Company Overview

9.17.2.  Product Offerings

9.17.3.  Financial Performance

9.17.4.  Recent Initiatives

9.18.                 Biolitec AG (Austria)

9.18.1.  Company Overview

9.18.2.  Product Offerings

9.18.3.  Financial Performance

9.18.4.  Recent Initiatives

9.19.                 Urologix, LLC (US)

9.19.1.  Company Overview

9.19.2.  Product Offerings

9.19.3.  Financial Performance

9.19.4.  Recent Initiatives

9.20.                 Advin Health Care (India)

9.20.1.  Company Overview

9.20.2.  Product Offerings

9.20.3.  Financial Performance

9.20.4.  Recent Initiatives

9.21.                 Medifocus, Inc. (Canada)

9.21.1.  Company Overview

9.21.2.  Product Offerings

9.21.3.  Financial Performance

9.21.4.  Recent Initiatives

9.22.                 Asclepion Laser Technologies GmbH (Germany)

9.22.1.  Company Overview

9.22.2.  Product Offerings

9.22.3.  Financial Performance

9.22.4.  Recent Initiatives

9.23.                 Pnn Medical A/S (Denmark)

9.23.1.  Company Overview

9.23.2.  Product Offerings

9.23.3.  Financial Performance

9.23.4.  Recent Initiatives

9.24.                 Surgical Lasers Inc. (Canada)

9.24.1.  Company Overview

9.24.2.  Product Offerings

9.24.3.  Financial Performance

9.24.4.  Recent Initiatives

9.25.                 Allium Ltd. (Israel)

9.25.1.  Company Overview

9.25.2.  Product Offerings

9.25.3.  Financial Performance

9.25.4.  Recent Initiatives

9.26.                 Lumenis Ltd. (Israel)

9.26.1.  Company Overview

9.26.2.  Product Offerings

9.26.3.  Financial Performance

9.26.4.  Recent Initiatives

9.27.                 KARL STORZ SE & Co. KG (Germany)

9.27.1.  Company Overview

9.27.2.  Product Offerings

9.27.3.  Financial Performance

9.27.4.  Recent Initiatives

9.28.                 SRS Medical (US)

9.28.1.  Company Overview

9.28.2.  Product Offerings

9.28.3.  Financial Performance

9.28.4.  Recent Initiatives

Chapter 10.   Research Methodology

10.1.                 Primary Research

10.2.                 Secondary Research

10.3.                 Assumptions

Chapter 11.   Appendix

11.1.                 About Us

11.2.                 Glossary of Terms